Singapore-based precision gut microbiome company Amili has secured an undisclosed amount in funding led by East Ventures.

The fresh capital will be used to expand its operations into Indonesia, with a primary focus on addressing common gut health problems using scientifically-based approaches tailored to the Indonesian context.

Established in 2019 by CEO Jeremy Lim, along with David Ong and Jonathan Lee, Amili conducts advanced gut microbe research and translates it into practical products and services.